Profit

NSE Symbol: | BSE Code: | ISIN: | Sector:

  • Add to Portfolio
  • Add to Watchlist
  • Add to Alert
  • Add to Message
Add to Portfolio
NSE
548.95
Change Change %
-2.60 -0.47%

Updated:24 Jun, 2019, 14:09 PM IST

BSE
548.55
Change Change %
-3.20 -0.58%

Updated:24 Jun, 2019, 14:09 PM IST

Chemical, Industrial & Pharmaceutical Laboratories, now known as Cipla, was incorporated 1935.Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorised capital of Rs 6 lakhs.

Business of the company:

The company focuses on development of new formulations and has a wide range of pharmaceutical products. It offers prescription drugs, bulk drugs, animal products and pesticides. It also offers a wide range of food and beverages, baked foods, oral hygiene products, detergents, room fresheners and personal care products.

Almost 55% of its overall income from its operations come from outside India. It has 5,500 registered products in various countries.Cipla offers drugs used for treatment of cancer, Alzheimer's, arthritis, Parkinson?óÔé¼Ôäós, cardiovascular diesases and many more. It also offers drugs that prevents transmission of AIDS from mother to child.The company provides consulting services on preparation of products and materials, conducts plant evaluation and supplies plant equipments.

Cipla has set up two institutes namely Dr K.A Hamied Institute and Cipla Cancer Palliative Care & Training Centre.It has a presence across 170 countries with manufacturing units approved by regulatory authorities like USFDA, WHO–Canada and MHRA–UK, among others.

Cipla was first company outside US and Europe to launch CFC–free inhalers. In 2007 Cipla launched oral emergency contraceptive pill under the brand name I–Pill. Cipla also launched a breakthrough screening technology in India called the ?óÔé¼?£No Touch Breast Scan (NTBS); ' the first–ever painless, non–invasive and radiation–free breast scanning technique for detecting breast cancer at an early stage.

In 2009, Cipla launched generic versions of anti–flu drugs oseltamivir and zanamivir in the local market to treat the H1N1 influenza, spreading across the globe and in India. In 2010, Piramal Healthcare Limited announced the signing of a definitive agreement with Cipla Limited for purchase of all intellectual property rights in India related to 'i–pill' for an aggregate consideration of Rs 95 crore.

Achievements:

The company won the Forbes Asia's ?óÔé¼?ôBest Under A Billion?óÔé¼?Ø List from Forbes Magazine.

Cipla also won the Most Profitable Company overall among those ?óÔé¼?ôUnder a Billion in the Region?óÔé¼Ôäós Top 200 Small and Mid Size companies?óÔé¼?Ø from Forbes Magazine.

Milestones:

1935–Dr K A Hamied sets up 'The Chemical, Industrial and Pharmaceutical Laboratories Ltd.' in a rented bungalow, at Bombay Central. 1941–As the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. 1952– Sets up first research division for attaining self–sufficiency in technological development. 1960– Starts operations at second plant at Vikhroli, Mumbai, producing fine chemicals with special emphasis on natural products. 1968– Cipla manufactures ampicillin for the first time in the country. 1972–Starts Agricultural Research Division at Bangalore, for scientific cultivation of medicinal plants. 1976–Cipla launches medicinal aerosols for asthma. 1980–Wins Chemexcil Award for Excellence for exports. 1982–Fourth factory begins operations at Patalganga, Maharashtra. 1984–Develops anti–cancer drugs, vinblastine and vincristine in collaboration with the National Chemical Laboratory, Pune.

Wins Sir P C Ray Award for developing inhouse technology for indigenous manufacture of a number of basic drugs. 1985–US FDA approves Cipla's bulk drug manufacturing facilities. 1988–Cipla wins National Award for Successful Commercialisation of Publicly Funded R&D. 1991–Lauches etoposide, a breakthrough in cancer chemotherapy, in association with Indian Institute of Chemical Technology.

The company pioneers the manufacture of the antiretroviral drug, zidovudine, in technological collaboration with Indian Institute of Chemical Technology, Hyderabad. 1994–Cipla's fifth factory begins commercial production at Kurkumbh, Maharashtra. 1997–Launches transparent Rotahaler, the world's first such dry powder inhaler device now patented by Cipla in India and abroad. The palliative cancer care centre set up by the Cipla Foundation, begins offering free services at Warje, near Pune.

 1998– Launches lamivudine, becoming one of the few companies in the world to offer all three component drugs of retroviral combination therapy (zidovudine and stavudine already launched). 1999–Launches Nevirapine, antiretroviral drug, used to prevent the transmission of AIDS from mother to child. 2000–Cipla became the first company, outside the USA and Europe to launch CFC–free inhalers ?óÔé¼ÔÇ£ ten years before the deadline to phase out use of CFC in medicinal products. 2002–Four state–of–the–art manufacturing facilities set up in Goa in a record time of less than twelve months. 2003–Launches TIOVA (Tiotropium bromide), a novel inhaled, long–acting anticholinergic bronchodilator that is employed as a once–daily maintenance treatment for patients with chronic obstructive pulmonary disease (COPD).Commissioned second phase of manufacturing operations at Goa. 2005–Sest–up state–of–the–art facility for manufacture of formulations at Baddi, Himachal Pradesh.

2007–Sets–up state–of–the–art facility for manufacture of formulations at Sikkim. 2010–Sets up state–of–the–art facility for manufacture of formulations at Indore.

Top